Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Chemotherapy-Induced Thrombocytopenia in Pediatric Solid Tumors
NCT04671901Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2020; status: terminated.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT04671901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671901.